Affiliations 

  • 1 Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand. kyeong.kim@canterbury.ac.nz
  • 2 Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand
  • 3 School of Engineering, Monash University, Bandar Sunway, Malaysia
  • 4 GIGA Cardiovascular Science, University of Liege, Liege, Belgium
  • 5 Department of Control Engineering and Information, Budapest University of Technology and Economics, Budapest, Hungary
  • 6 Institute of Technical Medicine (ITeM), HFU Furtwangen University, Villingen-Schwenningen, Germany
  • 7 Department of Intensive Care, Christchurch Hospital, Christchurch, New Zealand
Trials, 2020 Feb 01;21(1):130.
PMID: 32007099 DOI: 10.1186/s13063-019-4035-7

Abstract

BACKGROUND: Positive end-expiratory pressure (PEEP) at minimum respiratory elastance during mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS) may improve patient care and outcome. The Clinical utilisation of respiratory elastance (CURE) trial is a two-arm, randomised controlled trial (RCT) investigating the performance of PEEP selected at an objective, model-based minimal respiratory system elastance in patients with ARDS.

METHODS AND DESIGN: The CURE RCT compares two groups of patients requiring invasive MV with a partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 200; one criterion of the Berlin consensus definition of moderate (≤ 200) or severe (≤ 100) ARDS. All patients are ventilated using pressure controlled (bi-level) ventilation with tidal volume = 6-8 ml/kg. Patients randomised to the control group will have PEEP selected per standard practice (SPV). Patients randomised to the intervention will have PEEP selected based on a minimal elastance using a model-based computerised method. The CURE RCT is a single-centre trial in the intensive care unit (ICU) of Christchurch hospital, New Zealand, with a target sample size of 320 patients over a maximum of 3 years. The primary outcome is the area under the curve (AUC) ratio of arterial blood oxygenation to the fraction of inspired oxygen over time. Secondary outcomes include length of time of MV, ventilator-free days (VFD) up to 28 days, ICU and hospital length of stay, AUC of oxygen saturation (SpO2)/FiO2 during MV, number of desaturation events (SpO2 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.